Exhibit 99.5
RTI SURGICAL, INC. AND SUBSIDIARIES
Unaudited Pro Forma Condensed Combined Balance Sheet
As of June 30, 2013
(In thousands)
| | | | | | | | | | | | | | | | |
| | Historical | | | | | | | |
| | RTI Surgical, Inc. | | | Pioneer Surgical Technology, Inc. | | | Pro Forma Adjustments | | | Combined Pro Forma | |
| | | | | | | | (see note 2) | | | | |
Assets | | | | | | | | | | | | | | | | |
Current Assets: | | | | | | | | | | | | | | | | |
Cash and cash equivalents | | $ | 39,393 | | | $ | 918 | | | $ | (23,659 | ) a,s | | $ | 16,652 | |
Accounts receivable - net | | | 21,938 | | | | 12,300 | | | | — | | | | 34,238 | |
Inventories - net | | | 79,357 | | | | 28,608 | | | | 1,685 | b | | | 109,650 | |
Prepaid and other current assets | | | 6,467 | | | | 838 | | | | 116 | c | | | 7,421 | |
Deferred tax assets - net | | | 13,597 | | | | 5,385 | | | | (5,385 | ) d | | | 13,597 | |
Refundable taxes | | | — | | | | 673 | | | | — | | | | 673 | |
| | | | | | | | | | | | | | | | |
Total current assets | | | 160,752 | | | | 48,722 | | | | (27,243 | ) | | | 182,231 | |
Property, plant and equipment - net | | | 51,350 | | | | 16,083 | | | | — | | | | 67,433 | |
Deferred tax assets - net | | | 9,428 | | | | 4,113 | | | | (4,113 | ) d | | | 9,428 | |
Goodwill | | | 2,062 | | | | — | | | | 53,331 | r | | | 55,393 | |
Other intangible assets - net | | | 12,798 | | | | 1,504 | | | | 26,496 | e | | | 40,798 | |
Other assets - net | | | 638 | | | | 228 | | | | 13,464 | c,f | | | 14,330 | |
| | | | | | | | | | | | | | | | |
Total assets | | $ | 237,028 | | | $ | 70,650 | | | $ | 61,935 | | | $ | 369,613 | |
| | | | | | | | | | | | | | | | |
Liabilities and Stockholders’ Equity | | | | | | | | | | | | | | | | |
Current Liabilities: | | | | | | | | | | | | | | | | |
Accounts payable | | $ | 13,532 | | | $ | 4,320 | | | $ | — | | | $ | 17,852 | |
Accrued expenses | | | 16,226 | | | | 6,940 | | | | — | | | | 23,166 | |
Current portion of deferred revenue | | | 4,682 | | | | 277 | | | | — | | | | 4,959 | |
Current portion of long-term obligations | | | 27 | | | | 2,051 | | | | (2,051 | ) g | | | 27 | |
| | | | | | | | | | | | | | | | |
Total current liabilities | | | 34,467 | | | | 13,588 | | | | (2,051 | ) | | | 46,004 | |
Line of credit | | | — | | | | 3,357 | | | | (3,357 | ) g | | | — | |
Long-term obligations - less current portion | | | — | | | | 7,106 | | | | 52,894 | g,h | | | 60,000 | |
Other long-term liabilities | | | 696 | | | | 1,228 | | | | 13,000 | i | | | 14,924 | |
Deferred tax liabilities | | | 634 | | | | — | | | | 2,155 | d | | | 2,789 | |
Deferred revenue | | | 17,854 | | | | 455 | | | | — | | | | 18,309 | |
| | | | | | | | | | | | | | | | |
Total liabilities | | | 53,651 | | | | 25,734 | | | | 62,641 | | | | 142,026 | |
| | | | | | | | | | | | | | | | |
Common stock subject to redemption | | | — | | | | 201 | | | | (201 | ) j | | | — | |
Preferred stock - Series A | | | | | | | | | | | 48,710 | k | | | 48,710 | |
Commitments and contingencies | | | | | | | | | | | | | | | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | |
Common stock | | | 56 | | | | — | | | | — | | | | 56 | |
Preferred stock - Series A | | | — | | | | 65,000 | | | | (65,000 | ) j | | | — | |
Preferred stock - Series B | | | — | | | | 31,262 | | | | (31,262 | ) j | | | — | |
Notes receivable from sale of common stock | | | — | | | | (844 | ) | | | 844 | j | | | — | |
Additional paid-in capital | | | 415,752 | | | | — | | | | — | | | | 415,752 | |
Accumulated other comprehensive (loss) income | | | (2,091 | ) | | | 134 | | | | (134 | ) j | | | (2,091 | ) |
Accumulated deficit | | | (230,273 | ) | | | (50,837 | ) | | | 46,337 | j,s | | | (234,773 | ) |
Less treasury stock | | | (67 | ) | | | — | | | | — | | | | (67 | ) |
| | | | | | | | | | | | | | | | |
Total stockholders’ equity | | | 183,377 | | | | 44,715 | | | | (49,215 | ) | | | 178,877 | |
| | | | | | | | | | | | | | | | |
Total liabilities and stockholders’ equity | | $ | 237,028 | | | $ | 70,650 | | | $ | 61,935 | | | $ | 369,613 | |
| | | | | | | | | | | | | | | | |
See accompanying notes to unaudited pro forma condensed combined financial statements.
1
RTI SURGICAL, INC. AND SUBSIDIARIES
Unaudited Pro Forma Condensed Combined Statement of Comprehensive (Loss) Income
For the Six Months Ended June 30, 2013
(In thousands, except share and per share data)
| | | | | | | | | | | | | | | | |
| | Historical | | | | | | | |
| | RTI Surgical, Inc. | | | Pioneer Surgical Technology, Inc. | | | Pro Forma Adjustments | | | Combined Pro Forma | |
| | | | | | | | (see note 2) | | | | |
Revenues | | $ | 82,731 | | | $ | 42,113 | | | $ | (137 | ) l | | $ | 124,707 | |
Costs of processing and distribution | | | 44,299 | | | | 14,373 | | | | (137 | ) l | | | 58,535 | |
| | | | | | | | | | | | | | | | |
Gross profit | | | 38,432 | | | | 27,740 | | | | — | | | | 66,172 | |
| | | | | | | | | | | | | | | | |
| | | | |
Expenses: | | | | | | | | | | | | | | | | |
Marketing, general and administrative | | | 30,718 | | | | 25,188 | | | | 1,566 | e | | | 57,472 | |
Research and development | | | 6,452 | | | | 3,283 | | | | — | | | | 9,735 | |
Litigation settlement | | | 3,000 | | | | — | | | | — | | | | 3,000 | |
Acquisition expenses | | | 1,495 | | | | — | | | | (1,495 | ) m | | | — | |
| | | | | | | | | | | | | | | | |
Total expenses | | | 41,665 | | | | 28,471 | | | | 71 | | | | 70,207 | |
| | | | | | | | | | | | | | | | |
Operating (loss) income | | | (3,233 | ) | | | (731 | ) | | | (71 | ) | | | (4,035 | ) |
| | | | | | | | | | | | | | | | |
Other income (expense): | | | | | | | | | | | | | | | | |
Interest expense | | | — | | | | (112 | ) | | | (568 | ) c,n | | | (680 | ) |
Interest income | | | 9 | | | | 4 | | | | — | | | | 13 | |
Foreign exchange gain | | | (6 | ) | | | — | | | | — | | | | (6 | ) |
Other expense | | | — | | | | (405 | ) | | | — | | | | (405 | ) |
| | | | | | | | | | | | | | | | |
Total other income (expense) - net | | | 3 | | | | (513 | ) | | | (568 | ) | | | (1,078 | ) |
| | | | | | | | | | | | | | | | |
Loss before income tax benefit | | | (3,230 | ) | | | (1,244 | ) | | | (639 | ) | | | (5,113 | ) |
Income tax benefit | | | 1,693 | | | | 629 | | | | 251 | o | | | 2,573 | |
| | | | | | | | | | | | | | | | |
Net (loss) income | | | (1,537 | ) | | | (615 | ) | | | (388 | ) | | | (2,540 | ) |
| | | | | | | | | | | | | | | | |
Convertible preferred dividend | | | — | | | | — | | | | (1,500 | ) p | | | (1,500 | ) |
| | | | | | | | | | | | | | | | |
Net (loss) income applicable to common shares | | $ | (1,537 | ) | | $ | (615 | ) | | $ | (1,888 | ) | | $ | (4,040 | ) |
| | | | | | | | | | | | | | | | |
| | | | |
Other comprehensive (loss) income: | | | | | | | | | | | | | | | | |
Unrealized foreign currency translation (loss) gain, net of tax | | | (315 | ) | | | 67 | | | | — | | | | (248 | ) |
| | | | | | | | | | | | | | | | |
Comprehensive (loss) income | | $ | (1,852 | ) | | $ | (548 | ) | | $ | (1,888 | ) | | $ | (4,288 | ) |
| | | | | | | | | | | | | | | | |
| | | | |
Net loss per common share - basic | | $ | (0.03 | ) | | | | | | | | | | $ | (0.07 | ) |
| | | | | | | | | | | | | | | | |
Net loss per common share - diluted | | $ | (0.03 | ) | | | | | | | | | | $ | (0.07 | ) |
| | | | | | | | | | | | | | | | |
Weighted average shares outstanding - basic | | | 56,146,608 | | | | | | | | | | | | 56,146,608 | q |
| | | | | | | | | | | | | | | | |
Weighted average shares outstanding - diluted | | | 56,146,608 | | | | | | | | | | | | 56,146,608 | q |
| | | | | | | | | | | | | | | | |
See accompanying notes to unaudited pro forma condensed combined financial statements.
2
RTI SURGICAL, INC. AND SUBSIDIARIES
Unaudited Pro Forma Condensed Combined Statement of Comprehensive (Loss) Income
For the Year Ended December 31, 2012
(In thousands, except share and per share data)
| | | | | | | | | | | | | | | | |
| | Historical | | | | | | | |
| | RTI Surgical, Inc. | | | Pioneer Surgical Technology, Inc. | | | Pro Forma Adjustments | | | Combined Pro Forma | |
| | | | | | | | (see note 2) | | | | |
| | | | |
Revenues | | $ | 178,113 | | | $ | 88,180 | | | $ | (508 | ) l | | $ | 265,785 | |
Costs of processing and distribution | | | 92,896 | | | | 26,506 | | | | (508 | ) l | | | 118,894 | |
| | | | | | | | | | | | | | | | |
Gross profit | | | 85,217 | | | | 61,674 | | | | — | | | | 146,891 | |
| | | | | | | | | | | | | | | | |
| | | | |
Expenses: | | | | | | | | | | | | | | | | |
Marketing, general and administrative | | | 58,376 | | | | 51,304 | | | | 3,132 | e | | | 112,812 | |
Research and development | | | 12,231 | | | | 8,587 | | | | — | | | | 20,818 | |
Litigation settlement | | | 2,350 | | | | — | | | | — | | | | 2,350 | |
Asset abandonments | | | 20 | | | | — | | | | — | | | | 20 | |
| | | | | | | | | | | | | | | | |
Total expenses | | | 72,977 | | | | 59,891 | | | | 3,132 | | | | 136,000 | |
| | | | | | | | | | | | | | | | |
Operating income (loss) | | | 12,240 | | | | 1,783 | | | | (3,132 | ) | | | 10,891 | |
| | | | | | | | | | | | | | | | |
Other income (expense): | | | | | | | | | | | | | | | | |
Interest expense | | | — | | | | (571 | ) | | | (1,136 | ) c,n | | | (1,707 | ) |
Interest income | | | 185 | | | | 57 | | | | — | | | | 242 | |
Foreign exchange gain | | | 19 | | | | — | | | | — | | | | 19 | |
Gain on embedded Series B derivative | | | — | | | | 1,430 | | | | — | | | | 1,430 | |
Other expense | | | — | | | | (430 | ) | | | — | | | | (430 | ) |
| | | | | | | | | | | | | | | | |
Total other income (expense) - net | | | 204 | | | | 486 | | | | (1,136 | ) | | | (446 | ) |
| | | | | | | | | | | | | | | | |
Income before income tax (provision) benefit | | | 12,444 | | | | 2,269 | | | | (4,268 | ) | | | 10,445 | |
Income tax (provision) benefit | | | (4,042 | ) | | | 8,078 | | | | 1,622 | o | | | 5,658 | |
| | | | | | | | | | | | | | | | |
Net income (loss) | | | 8,402 | | | | 10,347 | | | | (2,646 | ) | | | 16,103 | |
| | | | | | | | | | | | | | | | |
Convertible preferred dividend | | | — | | | | — | | | | (3,000 | ) p | | | (3,000 | ) |
| | | | | | | | | | | | | | | | |
Net income (loss) applicable to common shares | | $ | 8,402 | | | $ | 10,347 | | | $ | (5,646 | ) | | $ | 13,103 | |
| | | | | | | | | | | | | | | | |
| | | | |
Other comprehensive income (loss): | | | | | | | | | | | | | | | | |
Unrealized foreign currency translation (loss) gain, net of tax | | | 408 | | | | (164 | ) | | | — | | | | 244 | |
| | | | | | | | | | | | | | | | |
Comprehensive income (loss) | | $ | 8,810 | | | $ | 10,183 | | | $ | (5,646 | ) | | $ | 13,347 | |
| | | | | | | | | | | | | | | | |
| | | | |
Net income per common share - basic | | $ | 0.15 | | | | | | | | | | | $ | 0.23 | |
| | | | | | | | | | | | | | | | |
Net income per common share - diluted | | $ | 0.15 | | | | | | | | | | | $ | 0.23 | |
| | | | | | | | | | | | | | | | |
Weighted average shares outstanding - basic | | | 55,861,957 | | | | | | | | | | | | 55,861,957 | q |
| | | | | | | | | | | | | | | | |
Weighted average shares outstanding - diluted | | | 56,068,795 | | | | | | | | | | | | 56,068,795 | q |
| | | | | | | | | | | | | | | | |
See accompanying notes to unaudited pro forma condensed combined financial statements.
3
RTI SURGICAL, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
(In thousands)
Note 1. Basis of Presentation
On July 16, 2013, RTI Surgical, Inc. (“RTI Surgical”) completed the acquisition of Pioneer Surgical Technology, Inc. (“Pioneer Surgical Technology”) which is described in the current report on Form 8-K filed on July 19, 2013. The accompanying unaudited pro forma condensed combined financial statements present the pro forma condensed combined financial position and results of operations of the combined company based upon the historical financial statements of RTI Surgical and Pioneer Surgical Technology, after giving effect to the Pioneer Surgical Technology acquisition and adjustments described in these footnotes, and are intended to reflect the impact of the acquisition on RTI Surgical.
On July 16, 2013, RTI Biologics, Inc. changed its name to RTI Surgical.
The unaudited pro forma condensed combined financial information was prepared using the acquisition method of accounting in accordance with Accounting Standards Codification, or ASC, Topic 805,Business Combinations, or ASC 805. ASC 805 requires, among other things, that most assets acquired and liabilities assumed be recognized at their acquisition date fair values and that the fair value of intangibles are recognized regardless of their intended use. The acquisition method of accounting uses the fair value concepts defined in ASC 820,Fair Value Measurements and Disclosures.ASC 820 defines the term “fair value” and sets forth the valuation requirements for any asset or liability measured at fair value, expands related disclosure requirements and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined in ASC 820 as “the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.” This is an exit price concept for the valuation of the asset or liability. In addition, market participants are assumed to be buyers and sellers in the principal (or the most advantageous) market for the asset or liability. Fair value measurements for an asset assume the highest and best use by market participants. Accordingly, RTI Surgical may be required to record assets which are not intended to be used or sold and/or to value assets at fair value measures that do not reflect RTI Surgical’ s intended use of such assets. Many of these fair value measurements can be highly subjective and it is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.
The accompanying unaudited pro forma condensed combined financial statements are presented for illustrative purposes only and do not give effect to any cost savings, revenue synergies or restructuring costs which may result from the integration of RTI Surgical and Pioneer Surgical Technology’s operations.
The unaudited pro forma condensed combined balance sheet reflects the acquisition as if it was completed on June 30, 2013 and includes estimated pro forma adjustments for RTI Surgical’ s preliminary internal valuations of all assets acquired and liabilities assumed. These adjustments are subject to further adjustment as additional information becomes available and additional analyses are performed. The unaudited pro forma condensed combined statements of comprehensive (loss) income reflect the acquisition as if it had been completed at the beginning of each period presented.
The pro forma condensed combined balance sheet has been adjusted to reflect the preliminary allocation of the purchase price to identifiable net assets acquired and liabilities assumed and the excess purchase price to goodwill. The purchase price allocation included within these unaudited pro forma condensed combined financial statements is based upon a preliminary cash purchase price of approximately $126,371.
4
The preliminary purchase price is as follows:
| | | | |
| | (in thousands) | |
Cash proceeds from term loan | | | 60,000 | |
Net cash proceeds from preferred share issuance | | | 48,710 | |
Cash from RTI Surgical | | | 17,661 | |
| | | | |
Total purchase price | | $ | 126,371 | |
| | | | |
The table below represents a preliminary allocation of the total consideration to Pioneer Surgical Technology’s tangible and intangible assets acquired and liabilities assumed based on management’s preliminary estimate of their respective fair values and potential fair value ranges as of June 30, 2013.
| | | | | | |
| | (in thousands) |
| | Fair Value at Acquisition | | | Fair Value Range |
Accounts receivable | | $ | 12,300 | | | $12,000 - $12,300 |
Inventory | | | 30,293 | | | 20,000 - 40,000 |
Prepaid and other current assets | | | 1,511 | | | 1,000 - 2,000 |
Property, plant and equipment, net | | | 16,083 | | | 15,000 - 20,000 |
Intangible assets, net | | | 28,000 | | | 20,000 - 40,000 |
Indemnification asset | | | 13,000 | | | 10,000 - 13,000 |
Other assets | | | 228 | | | 200 - 250 |
Accounts payable | | | (4,320 | ) | | (4,320) |
Other current liabilities | | | (7,217 | ) | | (5,000 - 10,000) |
Other non-current liabilities | | | (1,683 | ) | | (1,500 - 1,750) |
Indemnification liability | | | (13,000 | ) | | (10,000 -13,000) |
Deferred tax liabilities, net | | | (2,155 | ) | | (0 - 10,000) |
| | | | | | |
Total identifiable net assets acquired | | | 73,040 | | | |
Goodwill | | | 53,331 | | | 45,000 - 60,000 |
| | | | | | |
Estimated purchase price | | $ | 126,371 | | | |
| | | | | | |
Upon completion of the fair value assessment after the acquisition, RTI Surgical anticipates that the ultimate price allocation will differ from the preliminary assessment outlined above. The final amounts allocated to assets acquired and liabilities assumed could differ significantly from the amounts presented in the unaudited pro forma condensed combined financial statements. Any changes to the initial estimates of the fair value of the assets and liabilities will be recorded as adjustments to those assets and liabilities and residual amounts will be allocated to goodwill.
Note 2. Pro Forma Adjustments
The unaudited pro forma condensed combined financial statements have been adjusted for the following:
a. | To reflect cash paid for Pioneer Surgical Technology by RTI Surgical of $17,661, $580 of debt issuance costs, $4,500 of anticipated incremental acquisition costs and excluding $918 of Pioneer Surgical Technology’s cash as part of the debt free, cash free transaction. |
b. | A preliminary excess fair value estimate of $1,685 has been allocated to inventories acquired. The assumptions as to the fair value of Pioneer Surgical Technology’s inventory and the estimated useful lives may change as RTI Surgical conducts a valuation of Pioneer Surgical Technology’s inventory following the completion of the acquisition. The pro forma fair value adjustment to inventories acquired is based on Pioneer Surgical Technology’s inventories as of the date of the acquisition, adjusted as follows based on RTI Surgical management’s estimates using the following methods: |
| 1. | Finished goods at estimated selling prices less the sum of costs of disposal and a reasonable profit allowance for the selling effort of a market participant; |
5
| 2. | Work in process at estimated selling prices of finished goods less the sum of costs to complete, costs of disposal, and a reasonable profit allowance for the completing and selling effort of a market participant based on profit for similar finished goods; and |
| 3. | Raw materials at current replacement costs. |
c. | To reflect debt issuance costs as follows: |
| | | | | | | | | | | | | | | | |
| | Fair Value at Acquisition | | | Estimated Useful Lives (Years) | | | Pro Forma Amortization Expense for June 30, 2013 | | | Pro Forma Amortization Expense for December 31, 2012 | |
| | (in thousands) | |
| | | | |
Debt Issuance Costs - Current | | $ | 116 | | | | | | | $ | — | | | $ | — | |
Debt Issuance Costs - Long-term | | | 464 | | | | | | | | 58 | | | | 116 | |
| | | | | | | | | | | | | | | | |
Total | | $ | 580 | | | | 5 | | | $ | 58 | | | $ | 116 | |
| | | | | | | | | | | | | | | | |
d. | Represents the net deferred income tax liability, based on the statutory tax rates of the relevant jurisdictions. The effect of deferred taxes was estimated as follows: |
| | | | |
| | (in thousands) | |
Deferred income tax effect due to estimated fair value impact for: | | | | |
Inventory | | | 661 | |
Intangible assets | | | 10,992 | |
Indemnification asset | | | 5,103 | |
Indemnification liability | | | (5,103 | ) |
| | | | |
Estimated adjustments to deferred income taxes | | | 11,653 | |
Pioneer Surgical Technology’s historical deferred tax assets, net | | | (9,498 | ) |
| | | | |
Estimated deferred tax liability, net | | | 2,155 | |
| | | | |
The fair value range of Pioneer Surgical Technology’s historical deferred tax assets, net are expected to be between $7,000 and $10,000.
e. | To reflect the fair value of intangible assets acquired and additional amortization expense due to the adjustment of certain of Pioneer Surgical Technology’s intangible assets to fair value at the time of the acquisition. Pro forma amortization expense for the six months ended June 30, 2013 and the year ended December 31, 2012 of $1,566 and $3,132, respectively, was recorded utilizing the straight-line method of amortization for intangible assets: |
| | | | | | | | | | | | | | | | |
| | Book Value as of June 30, 2013 | | | Fair Value as of June 30, 2013 | | | Pro Forma Adjustment | | | Fair Value Range | |
| | (in thousands) | |
| | | | |
Intangibles, net | | $ | 1,504 | | | $ | 28,000 | | | $ | 26,496 | | | $ | 20,000 - $40,000 | |
6
The table below represents a preliminary allocation of the purchase price to certain long-lived intangible assets of Pioneer Surgical Technology. The preliminary allocation of the purchase price to identifiable intangible assets and the estimated useful lives is as follows:
| | | | | | | | | | | | | | | | |
| | Fair Value at Acquisition | | | Estimated Useful Lives (Years) | | | Pro Forma Amortization Expense for June 30, 2013 | | | Pro Forma Amortization Expense for December 31, 2012 | |
| | (in thousands) | |
| | | | |
Intellectual Property | | $ | 20,250 | | | | 10 | | | $ | 1,013 | | | $ | 2,025 | |
Distribution agreements | | | 6,750 | | | | 7 | | | | 482 | | | | 964 | |
Other | | | 1,000 | | | | 7 | | | | 71 | | | | 143 | |
| | | | | | | | | | | | | | | | |
Total | | $ | 28,000 | | | | | | | $ | 1,566 | | | $ | 3,132 | |
| | | | | | | | | | | | | | | | |
f. To reflect indemnification asset for potential litigation and working capital adjustments and long-term debt issuance costs as follows:
| | | | |
| | (in thousands) | |
Indemnification asset at acquisition | | $ | 13,000 | |
Debt issuance costs - long-term | | | 464 | |
| | | | |
Total | | $ | 13,464 | |
| | | | |
g. | To reflect elimination of Pioneer Surgical Technology’s historical debt accounts which were paid off at acquisition by Pioneer Surgical Technology as part of the debt free, cash free transaction. |
h. | To reflect the $60,000 term loan as partial payment for Pioneer Surgical Technology, net of the long-term portion of Pioneer Surgical Technology’s historical debt of $7,106. |
i. | To reflect the indemnification liability at acquisition for potential litigation and working capital adjustments of Pioneer Surgical Technology. |
j. | To reflect elimination of Pioneer Surgical Technology’s historical stockholders’ equity accounts. |
k. | To reflect $48,710 in net cash proceeds from RTI Surgical’ preferred share issuance as partial payment for Pioneer Surgical Technology. |
l. | To reflect elimination of intercompany revenues. |
m. | To reflect the elimination of direct acquisition costs incurred prior to the acquisition. |
n. | To reflect the amortization of debt issuance costs and interest expense on the $60,000 term loan at 1.70% per annum. |
o. | To reflect adjustments to income tax (provision) benefit for the pro forma adjustments at statutory rates. |
p. | To reflect the six month and full year convertible preferred dividend paid quarterly in arrears on the preferred share issuance. |
q. | No additional common shares were issued by RTI Surgical with respect to the acquisition of Pioneer Surgical Technology. At the time of the acquisition, the convertible preferred shares were anti-dilutive to the weighted average shares outstanding. |
r. | To reflect the pro forma impact of $53,331 of excess preliminary purchase price over the acquired assets and liabilities assumed. |
s. | To reflect anticipated incremental acquisition costs of $4,500. |
7